Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

Many pathogens use the same immune evasion mechanisms as cancer cells. Patients with chronic infections have elevated levels of checkpoint receptors (e.g., programed cell death 1, PD1) on T cells. Monoclonal antibody (mAb)-based inhibitors to checkpoint receptors have also been shown to enhance T-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotraiah, Vinayaka, Phares, Timothy W., Browne, Cecille D., Pannucci, James, Mansour, Marc, Noe, Amy R., Tucker, Kenneth D., Christen, Jayne M., Reed, Charles, MacKay, Alecia, Weir, Genevieve M., Rajagopalan, Rajkannan, Stanford, Marianne M., Chung, Chun-Shiang, Ayala, Alfred, Huang, Jing, Tsuji, Moriya, Gutierrez, Gabriel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068811/
https://www.ncbi.nlm.nih.gov/pubmed/32210956
http://dx.doi.org/10.3389/fimmu.2020.00264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068811/
https://www.ncbi.nlm.nih.gov/pubmed/32210956
http://dx.doi.org/10.3389/fimmu.2020.00264

Ejemplares similares